|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||2.2960 - 2.4100|
|52 Week Range||0.6637 - 3.2800|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO , May 13, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned and the Company is in the latter stages of securing local regulatory approvals in Uruguay for the completion of the Acquisition.
Proxy voting deadline is May 29, 2019 at 11 a.m. ( Toronto time). Board of Directors recommends that Shareholders vote FOR all resolutions. TORONTO , May 10, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America, today announced it has commenced the mailing of the management information circular and other related materials (collectively, the "Meeting Materials") to Khiron's shareholders ("Shareholders") in connection with the annual general and special meeting of Shareholders (the "Meeting").
In the news release, Khiron Life Sciences Enters into $25 Million Bought Deal Equity Financing, issued 06-May-2019 by Khiron Life Sciences Corp. over CNW, we are advised by the company that the first paragraph, last sentence, should read "Common Share of $2.90 " rather than "Common Share of $3.00 " as originally issued inadvertently. TORONTO , May 6, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America , announced today that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters (together, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, 8,621,000 common shares of the Company ("Common Shares"), on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.90 (the "Issue Price") for gross proceeds of $25,000,900 (the "Offering").
TORONTO, April 30, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that it has signed a distribution agreements for its Kuida® cosmeceutical brand with Cafam, a leading Colombian drugstore chain. This agreement further expands the brands points of sales In combination with the previous announced distribution arrangements this agreement further expands the brands retail and e-commerce points of sales in Colombia.
LOI with Copservir Ltda, Colombia's largest pharmacy chain with over 900 pharmacies across 200 cities and municipalities across the country, and sales of over CAD 500 Million per year It is anticipated ...
TORONTO, April 25, 2019 /PRNewswire/ -- Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a medical cannabis company with its core operations in Latin America, announced today that the Company has entered into a non-binding letter of agreement to acquire 100% of the outstanding securities of Canapalife S.r.l. Canapalife is a prominent hemp product company based in Italy with licenses for the cultivation, research, production and marketing of hemp-based products.
DENVER , April 25, 2019 /CNW/ - Dixie Brands (CSE: DIXI.U), (OTC: DXBRF), ( Frankfurt : 0QV), one of the cannabis industry's leading consumer packaged goods ("CPG") companies, today announces a partnership with FounderMade to exclusively host the "Future of CBD & Cannabis" lounge at the FounderMade Discovery Show in New York City this coming June. Renowned for creating an environment where bold, innovative, life-changing products can thrive, the FounderMade Discovery Show is a summit for next generation companies to showcase groundbreaking products to key industry players. A pioneer in the category for the past ten years, Dixie's Future of CBD & Cannabis lounge will champion the cannabis plant and spotlight the industry as it emerges from prohibition and enters the mainstream.
Cheap labor and optimum growing conditions have made Latin America an increasingly important player in cannabis cultivation. Kyle Detwiler, CEO of Northern Swan Holdings, a U.S. cannabis-focused investment fund, has made a big bet on Clever Leaves, a licensed medical cannabis producer in Colombia.
Khiron Appointments Larry Holifield, Former U.S. DEA Regional Director, Mexico and Central America as Khiron Security and Compliance Director, Mexico,- Joins Chief Compliance Officer Matt Murphy to Expand ...
Investorideas.com, a leading investor news resource covering cannabis stocks, releases a snapshot looking at the many cannabis companies looking into the CBD beauty and wellness sector and why this sector is gaining such momentum. According to one report from the GlobalWellnessInstitute, “a wellness mindset is starting to permeate the global consumer consciousness, affecting people’s daily decision-making – whether food purchases, a focus on mental wellness and reducing stress, incorporating movement into daily life, environmental consciousness, or their yearning for connection and happiness,” noted Katherine Johnston, senior research fellow, GWI. This change in mindset combined with growing interest from large retailers, most recently CVS and Walgreens, is making many companies invest in beauty and wellness.
TORONTO , April 10, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that it has entered into an agreement with the prominent Colombian research hospital, Centro Dermatológico Federico Lleras Acosta ("CDFLLA"). Pursuant to the terms of the agreement, Khiron and CDFLLA will establish a clinical research partnership focused on the effectiveness of medical cannabis for dermatological conditions.
TORONTO, April 9, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Latin America, announced today that it has signed a definitive agreement for the acquisition of NettaGrowth International Inc. ("NettaGrowth"), as previously announced on January 25, 2019. NettaGrowth will, at the time of the closing of the acquisition, own all of the outstanding shares of Dormul S.A. ("Dormul"), a Uruguayan company that has obtained the first licence to produce and export medical cannabis with THC for commercialization in Uruguay.
Seasoned capital markets leader and cannabis authority John Cooke is appointed VP of Corporate Development Luis Chavas to manage corporate development strategy and guide regulatory affairs for the Company ...
One of the largest and most influential cannabis conferences in Latin America Two-day conference to attract over 2,000 attendees from more than ten countries First Canadian Pavilion welcomes prominent ...
Retail distribution with Fedco, the first and most established specialized beauty retailer in Colombia , with 22 stores expanding reach to 50% of Colombia's territory Online distribution secured with Colombian ...